glp 1 drugs and blindness Lawsuits claiming Ozempic, other GLP-1s led to become second mass litigation over the π Optometrists are warning GLP-1
Description
With the development of the first GIP/GLP-1 co-agonist, tirzepatide, there has been an exponential increase in the effectiveness of incretin-mimetic pharmacological therapy for weight control in obese patients with and without diabetes
But GLP-1 does more than just regulate hunger and blood sugar
As shown in Fig
Step 2: Identify the dose and frequency
